iTeos Looking At A Strong Finish To 2024 After Going From Fifth To First In TIGIT

 
• By Kevin Grogan

Positive data on its anti-TIGIT antibody belrestotug meant ITeos provided one of the biggest stories at ESMO this year. CEO Michel Detheux told Scrip there was much more to come from the US-headquartered biotech founded in Belgium.

Cambridge, MA skyline
In 2018, iTeos shifted its headquarters from Belgium to Boston

More from Leadership

More from Interviews